Current role of image-guided robotic radiosurgery (Cyberknife ®) for prostate cancer treatment

BJU International

Volumn 111, Issue 5, 2013, Pages 761-766

  Seisen, Thomas ^b   Drouin, Sarah J ^b   Phé, Véronique ^b   Parra, Jérome ^b   Mozer, Pierre ^b   Bitker, Marc Olivier ^b   Cussenot, Olivier ^b   Rouprêt, Morgan ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT UNIVERSITAIRE DE FRANCE   (France)

Author keywords

Cyberknife ; hypofractionated radiation therapy; prostate cancer; stereotactic body radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; ERECTILE DYSFUNCTION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE; RADIOSURGERY; RETROSPECTIVE STUDY; ROBOTICS; SCORING SYSTEM; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT PLANNING;

DIAGNOSTIC IMAGING; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; HUMANS; INTRAOPERATIVE PERIOD; MALE; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOSURGERY; ROBOTICS; SURVIVAL RATE;

EID: 84876295891     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12000     Document Type: Article

References (28)

1. Choi C, Cho C, Kim G, Park K, Jo M, Lee C,. Stereotactic radiation therapy of localized prostate cancer using cyberknife. Int J Radiat Oncol Biol Phys 2007; 69: S375
2. SM Cyberknife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 2008; 70: 1588-1597
3. King CR, Brooks JD, Gill H,. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009; 73: 1043-1048
4. Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM,. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 2009; 8: 387-392
5. Meier R, Cotrutz C,. MRI-planned stereotactic body radiotherapy for organ-confined prostate cancer: feasibility and early results. Int J Radiat Oncol Biol Phys 2009; 75: S-2339
6. Aluwini S, Van Rooij P, Hoogeman M, et al. Cyberknife stereotactic radiotherapy as monotherapy for low to intermediate stage prostate cancer: early experience, feasibility and tolerance. J Endourol 2010; 24: 865-869
7. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M,. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol Cancer Res Treat 2010; 9: 575-582
8. Bolzicco G, Favretto MS, Scremin E, Tambone C, Tasca A, Guglielmi R,. Image-guidedstereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat 2010; 9: 473-477
9. McBride SM, Wong DS, Dombrowski JJ, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012; 118: 3681-3690
10. Freeman DE, King CR,. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol. 2011; 6: 3
11. Katz AJ, Santoro M, Ashley R, Diblasio F,. Stereotactic body radiotherapy for low- and Low-Intermediate Risk Prostate Cancer: is there a dose effect. Front Oncol 2011; 1: 49
12. Kang JK, Cho CK, Chi CW, et al. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 2011; 97: 43-48
13. King CR, Brooks JD, Gill H, Presti JCJ,. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82: 877-882
14. Jereczek-Fossa BA, Beltramo G, Fariselli L, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82: 889-897
15. King CR, Lehmann J, Adler JR, Hai J,. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat 2003; 2: 25-29
16. ® robotic radiosurgery system in 2010. Technol Cancer Res Treat 2010; 9: 433-452
17. Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L,. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72: 236-246
18. Hossain S, Xia P, Huang K, et al. Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 78: 58-63
19. Townsend NC, Huth BJ, Ding W, et al. Acute toxicity after CyberKnife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol 2011; 34: 6-10
20. Wiegner EA, King CR,. Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int J Radiat Oncol Biol Phys 2010; 78: 442-448
21. King CR, Lo A, Kapp DS,. Testicular dose from prostate Cyberknife: a cautionary note. Int J Radiat Oncol Biol Phys 2009; 73: 636-637
22. Fuller DB,. Testicular dose from prostate cyberknife: a cautionary note in regard to King et al. Int J Radiat Oncol Biol Phys 2009; 73: 637
23. Parthan A, Pruttivarasin N, Taylor D, et al. Cyberknife for prostate cancer: is it cost effective? J Clin Oncol 2011; (Suppl. 7); Abstract 87
24. Zietman A, Ibbott G,. Aclinical approach to technology assessment: how do we and how should we choose the right treatment? Semin Radiat Oncol 2012; 22: 11-17
25. Fraass BA, Moran JM,. Quality, technology and outcomes: evolution and evaluation of new treatments and/or new technology. Semin Radiat Oncol 2012; 22: 3-10
26. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP,. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002; 52: 6-13
27. Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS,. High-Dose-Rate Prostate Brachytherapy: an Excellent Accelerated-Hypofractionated Treatment for Favorable Prostate Cancer. Am J Clin Oncol 2010; 33: 481-488
28. Martin A, Gaya A,. Stereotactic body radiotherapy: a review. Clin Oncol (R Coll Radiol) 2010; 22: 157-172